Story
Electra Therapeutics Files for IPO to Fund Immune Disease and Cancer Drug Pipeline
Electra Therapeutics Inc., a clinical-stage biotechnology company, has filed for an initial public offering with the U.S. Securities and Exchange Commission. The San Francisco-based firm aims to raise capital to advance its pipeline of drugs targeting immune-mediated diseases and cancer.
Offering Details
According to the Friday filing, Electra plans to list its common stock on the Nasdaq Global Select Market under the ticker symbol ETRA. The company has not yet disclosed the number of shares it intends to offer or the proposed price range for the offering.
The underwriting syndicate for the IPO includes Jefferies, TD Cowen, Evercore ISI, and Cantor. The filing also revealed that the company's net loss widened to $61.98 million for the year ended Dec. 31, 2025, from $24.79 million in 2024, as research and development expenses more than doubled to $50.39 million. As of June 30, 2026, Electra held $97.73 million in cash, cash equivalents, and marketable securities.
Lead Drug Candidate
AdElectra's lead drug candidate is ipsoprubart, a monoclonal antibody developed to treat secondary hemophagocytic lymphohistiocytosis (sHLH). The company's filing describes sHLH as a severe hyperinflammatory syndrome with poor survival rates and no broadly approved therapies.
Ipsoprubart has received significant regulatory recognition, including Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) and PRIority MEdicine (PRIME) designation from the European Medicines Agency. The company is currently conducting a global Phase 2/3 registrational trial for the drug and expects to complete enrollment in the second half of 2027.
Expanding Pipeline
Beyond its lead candidate, Electra is also developing ELA822, another monoclonal antibody designed to selectively deplete activated T cells. This drug holds potential for treating various chronic T cell-mediated immune and inflammatory diseases. Electra initiated a Phase 1 clinical trial of ELA822 in healthy volunteers in Europe in August 2026.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.
Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.
Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.
DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.